Comparative Pharmacology
Head-to-head clinical analysis: ATRIDOX versus PANMYCIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ATRIDOX versus PANMYCIN.
ATRIDOX vs PANMYCIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ATRIDOX (doxycycline hyclate) is a tetracycline antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing aminoacyl-tRNA from binding to the A site. It also exhibits anti-inflammatory effects by inhibiting matrix metalloproteinases (MMPs) and reducing cytokine production.
Tetracycline antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing aminoacyl-tRNA from attaching to the A site.
50 mg subgingival controlled-release insert applied by dental professional into periodontal pockets once every 3 months.
250-500 mg PO q6h or 500 mg to 1 g IV q6h; maximum 4 g/day
None Documented
None Documented
Terminal half-life 16-18 hours; prolonged to 24-48 hours in renal impairment, requiring dose adjustment.
Terminal elimination half-life is 6-8 hours in patients with normal renal function. Half-life is significantly prolonged (up to 80 hours) in anuria, requiring dose adjustment.
Primarily renal (60-70% unchanged), biliary/fecal (10-15%) as active drug and metabolites; remainder metabolized.
Primarily renal excretion of unchanged drug via glomerular filtration; 80-90% recovered in urine within 24 hours. Biliary/fecal excretion accounts for <5%.
Category C
Category C
Tetracycline Antibiotic
Tetracycline Antibiotic